Ascelia Pharma Correlations
| ACE Stock | SEK 2.90 0.11 3.65% |
The current 90-days correlation between Ascelia Pharma AB and ExpreS2ion Biotech Holding is 0.02 (i.e., Significant diversification). The correlation of Ascelia Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Ascelia Pharma Correlation With Market
Average diversification
The correlation between Ascelia Pharma AB and DJI is 0.1 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Ascelia Pharma AB and DJI in the same portfolio, assuming nothing else is changed.
Ascelia |
The ability to find closely correlated positions to Ascelia Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ascelia Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ascelia Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ascelia Pharma AB to buy it.
Moving against Ascelia Stock
| 0.69 | XSPRAY | XSpray Pharma AB | PairCorr |
| 0.49 | HNSA | Hansa Biopharma AB | PairCorr |
| 0.47 | VITR | Vitrolife AB | PairCorr |
| 0.43 | CAMX | Camurus AB | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Risk-Adjusted Indicators
There is a big difference between Ascelia Stock performing well and Ascelia Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ascelia Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EXPRS2 | 4.06 | (0.95) | 0.00 | (0.63) | 0.00 | 6.78 | 59.10 | |||
| HNSA | 2.45 | (0.66) | 0.00 | (95.40) | 0.00 | 4.97 | 21.12 | |||
| SANION | 5.73 | 1.71 | 0.17 | (0.92) | 6.33 | 17.14 | 72.42 | |||
| ONCO | 2.26 | (0.06) | 0.00 | 0.14 | 0.00 | 3.83 | 34.67 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Ascelia Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Ascelia Pharma Corporate Management
Elected by the shareholders, the Ascelia Pharma's board of directors comprises two types of representatives: Ascelia Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascelia. The board's role is to monitor Ascelia Pharma's management team and ensure that shareholders' interests are well served. Ascelia Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascelia Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carl MD | Chief Officer | Profile | |
| Julie Brogren | Deputy Officer | Profile | |
| Magnus Corfitzen | Chief Officer | Profile | |
| Despina Hedin | Chief Officer | Profile | |
| Mikael Widell | Head Communications | Profile | |
| Andreas Norlin | Chief Officer | Profile |